Title |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib
|
---|---|
Published in |
Annals of Hematology, March 2017
|
DOI | 10.1007/s00277-017-2973-2 |
Pubmed ID | |
Authors |
Varinder Kaur, Arjun Swami |
Abstract |
Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naïve, heavily pre-treated, and high-risk CLL/SLL. With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase. As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged. New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets. Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL. We provide a comprehensive analysis of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 20% |
Spain | 1 | 20% |
Canada | 1 | 20% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
Unknown | 110 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 18 | 16% |
Researcher | 18 | 16% |
Student > Master | 14 | 13% |
Student > Bachelor | 14 | 13% |
Other | 7 | 6% |
Other | 20 | 18% |
Unknown | 20 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 31 | 28% |
Biochemistry, Genetics and Molecular Biology | 13 | 12% |
Chemistry | 13 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 7% |
Agricultural and Biological Sciences | 7 | 6% |
Other | 18 | 16% |
Unknown | 21 | 19% |